Meta-Analysis Links Pfizer’s Chantix to Cardiovascular Issues

Clinical data for Pfizer’s Chantix show an increased risk of serious adverse cardiovascular events, according to a new meta-analysis. The study, published Monday in the Canadian Medical Association Journal, looked at published Chantix (varenicline) trials through March and found ‘a significantly increased risk of adverse cardiovascular events compared with placebo.’
Drug Industry Daily